Samsung Bioepis Set to Launch Eylea Biosimilar in the U.S. Next January
Samsung Bioepis announced on the 12th that it has entered into a patent license agreement with the original developer regarding its low-dose (2mg)...
Search results for "product approval"
LigaChemBio Receives Milestone from Czech Sotio Biotech
LigaChem Biosciences announced on the 9th that it will receive milestone payments based on successful product development under the antibody-drug...
Eubiologics Reports Net Profit for Two Consecutive Years, What’s Next?
Cholera vaccine specialist Eubiologics has shown strong performance growth, recording net profits for two consecutive...
Samsung Bioepis Aflibercept Biosimilar Available for Sale in Europe
Samsung Bioepis announced on the 30th that it has signed a patent agreement and licensing contract with the original...
Dementia Injection Drug ‘Lecanemab’ Formulation and Dosage Diversification... Will It Compete with Oral Medications?
American Biogen and Japanese Eisai are moving quickly to change the formulation and dosage of the dementia treatment...
K-Toxins Heading to China... Will Hugel Be Followed After 5 Years in the Top 3?
Domestic botulinum toxin companies are racing towards the Chinese market. With Hugel, which entered China first,...
HK Innoen's 'K-Cab' Applies for New Drug Approval from the U.S. FDA
HK Innoen announced on the 13th that its U.S. partner, Sevela Pharmaceuticals, a subsidiary and specialist in...
Oral Obesity Drug Launched in the U.S.… Where is K-Bio Pharmaceutical Now?
Denmark's Novo Nordisk's obesity drug ‘Wegovy Pill (ingredient name Semaglutide)’ has recently been launched in the U. S.
Samsung Bioepis to Directly Sell Ophthalmic Drug Baivubiz in Europe
Samsung Bioepis announced on the 4th that it has recovered the European commercialization rights for the ophthalmic...